| ADVANZ-PHARMA-HOLDINGS |
ADVANZ-PHARMA-HOLDINGS |
85%
|
NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.) r. Revenue recognition: (Cont.) At contract inception, the Company assesses the goods or services agreed upon within each contract and assesses whethe… |
| MERCURY-PHARMA-GROUP-LIMITED |
MERCURY-PHARMA-GROUP-LIMITED |
85%
|
NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.) r. Revenue recognition: (Cont.) At contract inception, the Company assesses the goods or services agreed upon within each contract and assesses whethe… |
| BDX |
Becton, Dickinson and Company |
72%
|
we have incurred over the last two years pursuant to our research and development programs, please see “Item 5. Operating and Financial Review and Prospects— A. Operating Results— Operating Expenses—… |
| BDX |
Becton, Dickinson and Company |
72%
|
Reciprocal relationship from BDX graph: Reciprocal relationship from PYPD graph: Reciprocal relationship from BDX graph: Reciprocal relationship from PYPD graph: Reciprocal relationship from BDX grap… |
| MDT |
Medtronic plc |
72%
|
Reciprocal relationship from MDT graph: Reciprocal relationship from PYPD graph: Reciprocal relationship from MDT graph: Reciprocal relationship from PYPD graph: Reciprocal relationship from MDT grap… |
| MDT |
Medtronic plc |
72%
|
we have incurred over the last two years pursuant to our research and development programs, please see “Item 5. Operating and Financial Review and Prospects— A. Operating Results— Operating Expenses—… |
| PTIX |
Protagenic Therapeutics, Inc. |
72%
|
Reciprocal relationship from PTIX graph: Reciprocal relationship from PYPD graph: we have incurred over the last two years pursuant to our research and development programs, please see “Item 5. Opera… |
| PTIX |
Protagenic Therapeutics, Inc. |
72%
|
we have incurred over the last two years pursuant to our research and development programs, please see “Item 5. Operating and Financial Review and Prospects— A. Operating Results— Operating Expenses—… |
| ADDITIONALLY-POLYPID-INC |
ADDITIONALLY-POLYPID-INC |
62%
|
and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants … |
| ADVANZ-PHARMA-CORP |
ADVANZ-PHARMA-CORP |
62%
|
otification Rule apply to business associates of covered entities (i.e., entities that provide services to covered entities that may require access to or use of protected health information on behalf… |
| CME-GROUP |
CME-GROUP |
62%
|
to generate any revenue from product sales for at least the next few years. 87 Research and Development, Net Research and development, net consists primarily of costs incurred in connection with our … |
| DIAGNOSIS-RELATED-GROUP |
DIAGNOSIS-RELATED-GROUP |
62%
|
ations, impose requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, their business associates and covered subcontr… |
| FACEBOOK-IRELAND-LTD |
FACEBOOK-IRELAND-LTD |
62%
|
otification Rule apply to business associates of covered entities (i.e., entities that provide services to covered entities that may require access to or use of protected health information on behalf… |
| LIFE-SCIENCE-INTELLIGENCE-INC |
LIFE-SCIENCE-INTELLIGENCE-INC |
62%
|
perative period but have limited local bioavailability at the target tissue after the skin incision is closed. Attempts to prolong systemic antibiotic exposure after surgical closure via repeated dos… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
e held for the production of passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive in… |
